Literature DB >> 3665910

In vitro and in vivo synthesis of dolichol and other main mevalonate products in various organs of the rat.

P G Elmberger1, A Kalèn, E L Appelkvist, G Dallner.   

Abstract

The relative rate of biosynthesis of dolichol from [3H]mevalonate in nine rat organs was studied in slices and in the whole animal. This biosynthesis was also compared to that of cholesterol and ubiquinone. All tissues examined are able to synthesize dolichol, as well as ubiquinone and cholesterol. Comparison of the data from slices in vitro with the in vivo studies demonstrated relatively good agreement for dolichol and ubiquinone synthesis. Although dolichol of high specific radioactivity was recovered in the blood, redistribution between organs, such as occurs with cholesterol, appears to be insignificant. The highest rates of dolichol biosynthesis were found in kidney, spleen and liver. On the other hand, muscle makes the largest contribution to total body dolichol synthesis. Newly synthesized dolichol also appears in the bile, but excretion by this route is far from sufficient to account for dolichol turnover. Incorporation of mevalonate into the final products is mainly dependent on biosynthetic activity. For comparison of the biosynthetic rates in different organs, possible sources of errors (such as variations in the size of the precursor pool, limitation by the rate of precursor uptake or non-linear incorporation) were investigated the size of the mevalonate pool in various organs. Equilibration of this pool with exogenous mevalonate is a rapid and passive process. The size of the mevalonate pool does not determine the rates of cholesterol and dolichol biosynthesis, indicating the presence of regulatory steps in the terminal portion of these biosynthetic pathways.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3665910     DOI: 10.1111/j.1432-1033.1987.tb13379.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  20 in total

1.  Vitamins Q and E, extracorporal circulation and hemolysis.

Authors:  J Karlsson; R Ronneberg; B Semb
Journal:  Mol Cell Biochem       Date:  1997-08       Impact factor: 3.396

2.  Unequivocal evidence for endogenous geranylgeranoic acid biosynthesized from mevalonate in mammalian cells.

Authors:  Yoshihiro Shidoji; Yuki Tabata
Journal:  J Lipid Res       Date:  2019-01-08       Impact factor: 5.922

3.  Calorie restriction modifies ubiquinone and COQ transcript levels in mouse tissues.

Authors:  Cristina Parrado-Fernández; Guillermo López-Lluch; Elisabet Rodríguez-Bies; Sara Santa-Cruz; Plácido Navas; Jon J Ramsey; José M Villalba
Journal:  Free Radic Biol Med       Date:  2011-03-27       Impact factor: 7.376

Review 4.  The biological role of dolichol.

Authors:  T Chojnacki; G Dallner
Journal:  Biochem J       Date:  1988-04-01       Impact factor: 3.857

5.  Discharge of newly-synthesized dolichol and ubiquinone with lipoproteins to rat liver perfusate and to the bile.

Authors:  P G Elmberger; A Kalén; U T Brunk; G Dallner
Journal:  Lipids       Date:  1989-11       Impact factor: 1.880

6.  Analysis of ubiquinone and tocopherol levels in normal and hyperlipidemic human plasma.

Authors:  Y Zhang; M Eriksson; G Dallner; E L Appelkvist
Journal:  Lipids       Date:  1998-08       Impact factor: 1.880

7.  Dolichol biosynthesis in human malignant cells.

Authors:  A Henry; P W Stacpoole; C M Allen
Journal:  Biochem J       Date:  1991-09-15       Impact factor: 3.857

8.  Cloning of an Arabidopsis thaliana cDNA coding for farnesyl diphosphate synthase by functional complementation in yeast.

Authors:  D Delourme; F Lacroute; F Karst
Journal:  Plant Mol Biol       Date:  1994-12       Impact factor: 4.076

9.  Age-related changes in the lipid compositions of rat and human tissues.

Authors:  A Kalén; E L Appelkvist; G Dallner
Journal:  Lipids       Date:  1989-07       Impact factor: 1.880

10.  Uptake and metabolism of dolichol and cholesterol in perfused rat liver.

Authors:  A Kalén; M Söderberg; P G Elmberger; G Dallner
Journal:  Lipids       Date:  1990-02       Impact factor: 1.880

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.